NCT06087029: IMPROVE-AD

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

Recruiting now NA Last updated 20 February 2026

What this trial tests

NA trial testing TEVAR in Type B Aortic Dissection in 1,100 participants. Currently enrolling.

Timeline

14 April 2024

Primary endpoint
1 June 2030

30 June 2030

Quick facts

Lead sponsor	Duke University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	1,100
Start date	14 April 2024
Primary completion	1 June 2030
Estimated completion	30 June 2030
Sites	62 locations across Canada, United States

Drugs / interventions tested

• TEVAR
• Guideline directed medical therapy and surveillance of dissection

Conditions studied

• Type B Aortic Dissection — all drugs for Type B Aortic Dissection →

Sponsor

Duke University

Who can join

21 and older, any sex, with Type B Aortic Dissection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Predicting Late Adverse Events in Uncomplicated Stanford Type B Aortic Dissection: Results From the ROADMAP Validation Study.
   Fleischmann D, Mastrodicasa D, Willemink MJ, Turner VL, et al · · 2025 · cited 2× · PMID 39965039 · DOI 10.1161/circimaging.124.016766